Research-based patient information · mainly adults aged 16+
Glioma: diagnosis, function and treatment choices
Glioma is a family of central nervous system tumours, not one diagnosis. In modern adult practice, histology and molecular markers are interpreted together. The adult pathway below must not be copied into paediatric care.
AI-generated educational anatomy and fictional camera movement. It does not depict an actual patient, scan, diagnosis, procedure or treatment outcome.
01
What a glioma is
The current WHO adult-type diffuse glioma taxonomy includes astrocytoma, IDH-mutant; oligodendroglioma, IDH-mutant and 1p/19q-codeleted; and glioblastoma, IDH-wildtype. IDH status, 1p/19q status where relevant, histology, grade and location are integrated because the word ‘glioma’ alone is not a complete diagnosis.
A scan can suggest a glioma but usually cannot establish its complete molecular identity. Paediatric tumours have different entities and treatment pathways.
02
Possible symptoms
A first seizure, progressive weakness or sensory change, language or visual difficulty, personality or cognitive change, worsening headache, repeated vomiting or drowsiness may occur depending on location and pressure. Some tumours are discovered incidentally. No symptom or scan appearance alone confirms the diagnosis.
03
Assessment and tests
- Neurological examination and MRI with sequences suited to tumour planning.
- Specialist multidisciplinary review from the first radiological suspicion when possible.
- Biopsy or resection to obtain tissue when this will guide care, with histology and molecular testing integrated into the diagnosis.
- Baseline assessment of language, movement, cognition, seizures, independence and rehabilitation needs.
- NICE NG99 is a UK evidence reference for people aged 16 and over, not a local timetable or guarantee.
04
Observation and non-operative options
Careful imaging surveillance can be appropriate for selected low-risk or incidentally found lesions when the multidisciplinary team judges that immediate tissue diagnosis or treatment would not improve the balance of benefit and harm. A suspected infiltrating tumour should not simply be ignored because symptoms are mild.
Radiotherapy or chemotherapy may follow the integrated diagnosis. UK NICE TA1147 recommends vorasidenib only for selected people aged 12 or over with grade 2 astrocytoma or oligodendroglioma carrying a susceptible IDH1 or IDH2 mutation, after surgery, when immediate radiotherapy or chemotherapy is not needed. This is a jurisdiction-specific eligibility decision for the treating neuro-oncology team, not a general option for every glioma.
05
The role of surgery
Surgery may establish diagnosis, reduce pressure, improve seizure control and remove as much tumour as is safely possible. When resection would threaten essential language, movement, vision or other function, biopsy or a limited operation may be safer.
Awake mapping, neurophysiological monitoring and image guidance can support selected operations. These tools reduce uncertainty but do not remove all risk, and glioblastoma surgery is not curative.
06
Your care pathway
- Specialist MRI and neurological assessment.
- Multidisciplinary discussion of whether observation, biopsy or resection is the safest next step.
- Integrated tissue and molecular diagnosis when tissue is obtained.
- Shared plan for surveillance, radiotherapy, systemic treatment, rehabilitation and symptom support.
- Follow-up of function and wellbeing alongside imaging, with rapid reassessment if new deficits appear.
07
Uncertainty and follow-up
The visible edge on MRI may not equal the biological edge of an infiltrating tumour. After radiotherapy or systemic treatment, treatment effect can look like progression, while a stable scan does not describe every functional concern.
Follow-up intervals and expected outcomes are individual. Questions should cover what is known, what molecular information changes, what function is at risk and how the team would respond to progression or treatment effects.